Physicians should encourage pharmaceutical companies to make socially responsible funding decisions and take an active role in setting biomedical research priorities by advocating for fair and effective allocations of public and private biomedical R & D investments.
A Canadian physician reports there is systematic bias to the outcome of published research funded by the pharmaceutical industry and believes more steps need to be taken to improve the integrity of clinical research reports in the United States and Canada.
The Domenici Wellstone Equitable Treatment Act sought to increase access to mental health care services and improve the efficiency and fairness of insurance coverage for mental illness.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
The Declaration of Helsinki was recently revised to require that the control arm of a trial use the current standard of care, even if that standard is not generally available in developing nations where the research is being conducted.